Llwytho...
Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells
BACKGROUND: The monocarboxylate transporter-1 (MCT1) represents a novel target in rational anticancer drug design while AZD3965 was developed as an inhibitor of this transporter and is undergoing Phase I clinical trials (http://www.clinicaltrials.gov/show/NCT01791595). We describe the optimisation o...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | BMC Cancer |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BioMed Central
2015
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4436118/ https://ncbi.nlm.nih.gov/pubmed/25957999 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1382-y |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|